Quick Answer
Forte Biosciences, Inc. reported Long-Term Debt of $26.20 million for fiscal year 2018.
Forte Biosciences, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2018 | $26.20M | +622.8% |
| 2017 | $3.62M | -64.6% |
| 2016 | $10.24M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| June 30, 2019 | $22.08M | -14.8% | -8.5% |
| March 31, 2019 | $24.14M | +1124.1% | -7.9% |
| December 31, 2018 | $26.20M | +622.8% | +0.6% |
| September 30, 2018 | $26.06M | +393.9% | +0.6% |
| June 30, 2018 | $25.91M | +274.0% | +1214.0% |
| March 31, 2018 | $1.97M | -77.0% | -45.6% |
| December 31, 2017 | $3.62M | -64.6% | -31.3% |
| September 30, 2017 | $5.28M | — | -23.8% |
- Forte Biosciences, Inc. showed an increase of +622.8% in Long-Term Debt compared to the prior fiscal year.
- Over the 2016–2018 period, Forte Biosciences, Inc.’s long-term debt has grown by 155.8% (from $10.24 million to $26.20 million).
- The most recent figure is from Forte Biosciences, Inc.’s fiscal year 2019 report (Form 10-K), filed with the SEC on February 27, 2020.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: